financetom
Business
financetom
/
Business
/
Tyson Foods says it has succession plans after executive's shock departure
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tyson Foods says it has succession plans after executive's shock departure
Sep 4, 2025 11:31 AM

CHICAGO (Reuters) -Tyson Foods sought to reassure investors that it has succession plans in place on Thursday, after announcing this week that an executive seen by some analysts as a possible future CEO left the company over conduct violations.

The meatpacker said late on Tuesday that Chief Supply Chain Officer Brady Stewart, who has also overseen its beef, pork and prepared foods businesses, ran afoul of its code of conduct. Tyson representatives have not responded to questions about the violations.

The company appointed Devin Cole, who led its poultry and international businesses, as chief operating officer and said he will oversee those units plus beef, pork and prepared foods.

Shares fell to a one-month low on Wednesday as the management change caught investors and analysts by surprise. Some had considered Stewart, a former COO for Smithfield Foods, as a candidate to eventually succeed Tyson CEO Donnie King.

"We have a very robust succession mechanism in place at our company," Cole said on a webcast of the Barclays Global Consumer Staples Conference.

When asked about his expanded role, Cole said he had been around the beef, pork and prepared foods businesses during his time at Tyson, and did not expect major changes.

"This is thankfully not just a complete surprise to me or others," he said.

Tyson has grappled with cautious consumer spending and its beef business has been losing money as low U.S. cattle supplies have forced meatpackers to pay more to buy livestock to slaughter. But the company raised its annual revenue forecast last month as quarterly profit margins improved in its chicken, pork and prepared foods units.

"Brady had done a good job improving Tyson's relative performance in beef, pork and prepared foods, and I'd thought he was the heir apparent," said Heather Jones, founder of Heather Jones Research, which focuses on agriculture and meat companies. 

"His departure was a shock."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
Oct 3, 2025
05:18 PM EDT, 10/03/2025 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on October 01, 2025, sold 8,924 shares in Alnylam Pharmaceuticals ( ALNY ) for $4,034,085. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 65,816 common shares of the company, with 65,409 shares held directly and 407 controlled indirectly. SEC Filing:...
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Oct 3, 2025
05:15 PM EDT, 10/03/2025 (MT Newswires) -- Todd Watanabe, Director, President and Chief Executive Officer, on October 01, 2025, sold 45,000 shares in Arcutis Biotherapeutics ( ARQT ) for $884,649. Following the Form 4 filing with the SEC, Watanabe has control over a total of 1,079,574 common shares of the company, with 846,440 shares held directly and 233,134 controlled indirectly....
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
Oct 3 (Reuters) - Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing...
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing that such expenses...
Copyright 2023-2026 - www.financetom.com All Rights Reserved